• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

    10/22/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRTC alert in real time by email

    Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone's differentiated profile and potential to address unmet needs across age groups

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). The data show that the favorable safety and efficacy profile of deupirfenidone was consistent across age groups, including in patients aged 75 years and older. These findings, presented at the American College of Chest Physicians (CHEST) 2025 Annual Meeting, suggest that deupirfenidone may address a key gap in the treatment of IPF, as older patients have historically been less likely to be treated, largely due to tolerability challenges.1,2 These data further reinforce deupirfenidone's differentiated profile and support its potential to meaningfully improve care for this vulnerable population.

    "These data are a welcome indication that age does not necessarily translate to a poorer treatment experience in IPF, which is generally a disease of older people," said Tejaswini Kulkarni, MD, MPH, Associate Professor of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham, who presented the data at CHEST 2025. "Older people with IPF have historically been undertreated and underrepresented in clinical trials because antifibrotic medications can be especially difficult to tolerate for this demographic. Demonstrating consistent safety and efficacy, particularly in this population, reinforces the differentiated profile of deupirfenidone and its potential to benefit a broad range of patients living with IPF."

    ELEVATE IPF was a randomized, double-blind, active- and placebo-controlled Phase 2b trial evaluating deupirfenidone 825 mg TID and deupirfenidone 550 mg TID compared to placebo and pirfenidone 801 mg TID in patients with IPF. This sub-analysis primarily focused on safety and tolerability in patients aged ≥75 years (n=91) compared with those aged <75 years (n=166), as tolerability challenges are a primary barrier to treatment in older populations. Treatment emergent adverse events, including gastrointestinal events, were similar for both age groups, indicating that older patients tolerated deupirfenidone comparably to younger patients. For example, the rates of nausea in patients aged ≥75 years vs. <75 years were 18.2% vs. 21.4% for deupirfenidone 825 mg TID; 14.3% vs. 18.2% for deupirfenidone 550 mg TID; 25.9% vs. 27.8% for pirfenidone 801 mg TID; and 9.5% vs. 6.8% for placebo. Efficacy also remained consistent with previously reported results, providing additional support for deupirfenidone's differentiated profile in this patient population.

    "Older patients represent a large and growing segment of the IPF population, yet they've historically been less likely to receive treatment due to concerns around tolerability," said Camilla Graham, MD, MPH, Senior Vice President of Medical Affairs at PureTech. "These findings highlight deupirfenidone's potential to be an attractive treatment option for a broader range of patients, including those who have often been underserved, while maintaining the strong efficacy profile demonstrated in the Phase 2b trial."

    About Deupirfenidone (LYT-100)

    Deupirfenidone (LYT-100) is in development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF). It is a next generation antifibrotic and a deuterated form of pirfenidone, one of three FDA-approved therapies for IPF. The uptake and adherence to approved antifibrotics has historically been limited by a tradeoff between modest efficacy and tolerability, and only ~25% of people with IPF in the U.S. had ever received treatment as of 2019.3

    Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining a favorable safety and tolerability profile. Initial data from an ongoing open-label extension study suggest this effect may be sustained through at least 52 weeks. These findings support the potential for deupirfenidone to offer a meaningful advance for people living with this progressive and deadly disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic conditions, including progressive fibrosing interstitial lung diseases.

    About Idiopathic Pulmonary Fibrosis (IPF)

    Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung disease characterized by irreversible scarring of lung tissue that leads to a steady decline in lung function. Median survival following diagnosis is estimated to be two to five years, and currently there is no cure.4

    About Celea Therapeutics

    Celea Therapeutics is dedicated to advancing transformative treatments for people with serious respiratory diseases. Drawn from the Latin word for "sky," the name reflects the company's mission to rise above the status quo and deliver therapies that change lives. The company's lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases.

    Celea was founded by PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)), a biotherapeutics company dedicated to giving life to science. PureTech's innovative R&D model drives the creation of Founded Entities like Celea, enabling the advancement of highly promising medicines to patients in a capital-efficient manner. For more information, please visit www.celeatx.com and www.puretechhealth.com.

    About PureTech Health

    PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.

    For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to continued development of and regulatory interactions related to deupirfenidone, the potential of deupirfenidone in IPF and other indications, our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

    ______________________________

    1 Qiu, Y., Zhu, J., Chopra, P., Elpers, B., Dieyi, C., Byrne, C., Tang, J., Wang, Y., Govindaraj, K., & Fischer, A. (2024). Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States. Therapeutic Advances in Respiratory Disease, 18. https://doi.org/10.1177/17534666241280704

    2 Cilli, A., Ocal, N., Uzer, F., Coskun, F., Sevinc, C., Ursavas, A., Yıldız, P., Deniz, P. P., Demirci, N. Y., Ozbey, G., Yurttas, A., & Hanta, I. (2023). Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions. Respiratory Investigation, 61(4), 490–497. https://doi.org/10.1016/j.resinv.2023.04.007

    3 Dempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah, N. D., & Limper, A. H. (2021). Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Annals of the American Thoracic Society, 18(7), 1121–1128.

    4 Fisher, M., Nathan, S. D., Hill, C., Marshall, J., Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. Journal of Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17–S24. https://doi.org/10.18553/jmcp.2017.23.3-b.s17

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251021394027/en/

    PureTech

    Public Relations

    [email protected]

    Investor Relations

    [email protected]

    UK/EU Media

    Ben Atwell, Rob Winder

    +44 (0) 20 3727 1000

    [email protected]

    US Media

    Justin Chen

    [email protected]

    Get the next $PRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRTC

    DatePrice TargetRatingAnalyst
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

    Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone's differentiated profile and potential to address unmet needs across age groups PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). The data show that the favorable safety and efficacy profile of deupirfenidone was consistent across age groups, including in patients aged 75 years and older. These findings, pres

    10/22/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

    Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability Findings further substantiate safety and efficacy results from the randomized, placebo- and active-controlled 26-week trial and highlight opportunity to address patients inadequately served by current therapies Regulatory engagement underway; update on Phase 3 trial design expected in Q4 2025 PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced new data from the op

    9/29/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers

    GlyphAgo is an oral prodrug of agomelatine, a medicine with established clinical efficacy in generalized anxiety disorder (GAD) GlyphAgo is designed to overcome a key limitation of agomelatine by shifting absorption toward the intestinal lymphatics, avoiding first-pass liver metabolism, and increasing systemic exposure of the drug Phase 1 proof-of-concept study will evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo and is designed to demonstrate therapeutic levels of agomelatine at lower doses that reduce liver exposure PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to scie

    9/11/25 7:05:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on PureTech Health plc with a new price target

    Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

    9/9/24 7:42:36 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $70.00 from $76.00 previously

    1/7/22 4:34:06 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on PureTech Health with a new price target

    SVB Leerink reiterated coverage of PureTech Health with a rating of Outperform and set a new price target of $76.00 from $74.00 previously

    8/25/21 4:40:14 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    SEC Filings

    View All

    SEC Form 6-K filed by PureTech Health plc

    6-K - PureTech Health plc (0001782999) (Filer)

    8/28/25 6:47:31 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by PureTech Health plc

    SCHEDULE 13G - PureTech Health plc (0001782999) (Subject)

    8/11/25 1:05:29 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PureTech Health plc

    6-K - PureTech Health plc (0001782999) (Filer)

    7/16/25 6:30:13 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Announces Leadership Transition

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announces that Bharatt Chowrira, PhD, JD, has stepped down today from his role as Chief Executive Officer (CEO) and as a member of the Board of Directors. The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTe

    7/16/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Appoints Peel Hunt as Joint UK Corporate Broker

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeut

    4/9/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $PRTC
    Financials

    Live finance-specific insights

    View All

    PureTech Health: Notice of Half-Yearly Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2025, on Thursday, August 28, 2025. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep port

    8/18/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Health: Notice of Results

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

    4/23/25 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

    Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and deupirfenidone 825 mg TID and successfully demonstrated dose-dependent response Decline in lung function seen with deupirfenidone 825 mg TID as a monotherapy was -21.5 mL; natural lung function decline expected in healthy adults >60 years is ~-15 to ~-25 mL2; decline in lung function with pirfenidone 801 mg TID was -51.6 mL Deupirfenidone 825 mg TID showed strong, consistent and durable efficacy with a treatment effect versus placebo of 80.9% with favorable tolerability, while pirfenidone 801 mg TID had a 54.1% treatment effect versus placebo De

    12/16/24 2:00:00 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PureTech Health plc

    SC 13G - PureTech Health plc (0001782999) (Subject)

    11/12/24 1:29:13 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PureTech Health plc

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    11/7/24 9:47:57 AM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by PureTech Health plc (Amendment)

    SC 13G/A - PureTech Health plc (0001782999) (Subject)

    2/12/24 4:48:30 PM ET
    $PRTC
    Biotechnology: Pharmaceutical Preparations
    Health Care